therapy

July 12, 2017 is a historic day for the development of gene and cell-based therapies in the world. On that day the FDA approved CTL019 (tisagenlecleucel) of Novartis as a therapeutic option to cope with relapsed or refractory B-cell acute lymphoblastic leukemia in children and adolescents. Here are The CAR T-Cell Therapy Definition, Works, Cost, Side Effects, and Clinical Evidence